Ortoma AB Series B (ORT-B) - Net Assets
Based on the latest financial reports, Ortoma AB Series B (ORT-B) has net assets worth Skr142.72 Million SEK (≈ $15.36 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr161.34 Million ≈ $17.36 Million USD) and total liabilities (Skr18.63 Million ≈ $2.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Ortoma AB Series B for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr142.72 Million |
| % of Total Assets | 88.46% |
| Annual Growth Rate | 2.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 26.96 |
Ortoma AB Series B - Net Assets Trend (2021–2025)
This chart illustrates how Ortoma AB Series B's net assets have evolved over time, based on quarterly financial data. Also explore ORT-B total asset value for the complete picture of this company's asset base.
Annual Net Assets for Ortoma AB Series B (2021–2025)
The table below shows the annual net assets of Ortoma AB Series B from 2021 to 2025. For live valuation and market cap data, see market value of Ortoma AB Series B.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr142.72 Million ≈ $15.36 Million |
-11.85% |
| 2024-12-31 | Skr161.91 Million ≈ $17.42 Million |
-6.70% |
| 2023-12-31 | Skr173.54 Million ≈ $18.68 Million |
+51.84% |
| 2022-12-31 | Skr114.29 Million ≈ $12.30 Million |
-12.11% |
| 2021-12-31 | Skr130.04 Million ≈ $13.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ortoma AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr18.57 Million | 13.02% |
| Other Components | Skr124.14 Million | 86.98% |
| Total Equity | Skr142.72 Million | 100.00% |
Ortoma AB Series B Competitors by Market Cap
The table below lists competitors of Ortoma AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acanthe Développement
PA:ACAN
|
$39.19 Million |
|
Resource Mining Corporation Ltd
AU:RMI
|
$39.19 Million |
|
EYG Gayrimenkul Yatirim Ortakligi A.S.
IS:EYGYO
|
$39.20 Million |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
$39.22 Million |
|
Medicamen Biotech Limited
NSE:MEDICAMEQ
|
$39.14 Million |
|
Orient Precision Industries Inc
KQ:065500
|
$39.13 Million |
|
Yotta Acquisition Corporation Common Stock
NASDAQ:YOTA
|
$39.11 Million |
|
Bubang Co. Ltd
KQ:014470
|
$39.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ortoma AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 161,907,935 to 142,715,022, a change of -19,192,913 (-11.9%).
- Net loss of 19,192,912 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-19.19 Million | -13.45% |
| Other Changes | Skr-1.00 | -0.0% |
| Total Change | Skr- | -11.85% |
Book Value vs Market Value Analysis
This analysis compares Ortoma AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.55x to 2.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | Skr5.49 | Skr8.50 | x |
| 2022-12-31 | Skr4.82 | Skr8.50 | x |
| 2023-12-31 | Skr4.68 | Skr8.50 | x |
| 2024-12-31 | Skr4.37 | Skr8.50 | x |
| 2025-12-31 | Skr3.85 | Skr8.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ortoma AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.69%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.13x
- Recent ROE (-13.45%) is below the historical average (-11.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -8.30% | 0.00% | 0.00x | 1.03x | Skr-23.79 Million |
| 2022 | -13.78% | 0.00% | 0.00x | 1.32x | Skr-27.18 Million |
| 2023 | -12.60% | -57.35% | 0.20x | 1.11x | Skr-39.23 Million |
| 2024 | -7.18% | -23.68% | 0.27x | 1.12x | Skr-27.82 Million |
| 2025 | -13.45% | -29.69% | 0.40x | 1.13x | Skr-33.46 Million |
Industry Comparison
This section compares Ortoma AB Series B's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $407,399,619
- Average return on equity (ROE) among peers: -74.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ortoma AB Series B (ORT-B) | Skr142.72 Million | -8.30% | 0.13x | $39.18 Million |
| Acarix A/S (ACARIX) | $38.17 Million | -125.99% | 0.27x | $33.47 Million |
| Arcoma AB (ARCOMA) | $45.19 Million | 14.63% | 0.84x | $13.33 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $386.69 Million | 4.20% | 0.66x | $53.12 Million |
| BICO Group AB (BICO) | $3.10 Billion | -37.83% | 0.95x | $140.79 Million |
| Boule Diagnostics AB (BOUL) | $119.08 Million | 0.00% | 0.39x | $14.13 Million |
| CellaVision AB (CEVI) | $290.38 Million | 30.54% | 0.28x | $319.31 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $33.00 Million | -64.44% | 0.36x | $14.44 Million |
| Chordate Medical Holding AB (CMH) | $15.09 Million | -193.46% | 0.46x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $40.05 Million | -52.90% | 0.84x | $123.41 Million |
| Duearity AB (DEAR) | $6.06 Million | -318.56% | 0.99x | $331.97K |
About Ortoma AB Series B
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and … Read more